Experience

Amgen España

• Spain
• Biotechnology Research
• 1 - 100 Employee

• Head of Policy & Government Affairs

  • Oct 2018 - Present



Foment del Treball Nacional

• Spain
• Civic and Social Organizations
• 1 - 100 Employee

• Member of the President's Advisory Board

  • Nov 2022 - Present



Gilead Sciences

• United States
• Biotechnology Research
• 700 & Above Employee

• Government Affairs Senior Manager

  • Mar 2016 - Oct 2018



European Commission

• Belgium
• Government Administration
• 700 & Above Employee

• SME Instrument and Fast Track Program Independent Expert

  • May 2014 - Mar 2016

  Independent evaluation of Small and Medium Enterprises (SMEs) development proposals in the health and biotech fields, for the assignment of the "EC-SME Instrument" support. http://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument The SME instrument has been designed for highly innovative SMEs with international ambitions, determined to turn strong, innovative business ideas into winners on the market. The instrument provides full-cycle business innovation support from the stage of business idea conception and planning (phase I) over business plan execution and demonstration (phase II) to commercialisation (phase III).



Universitat Pompeu Fabra

• Spain
• Higher Education
• 700 & Above Employee

• Director / Senior Research Fellow

  • Sep 2011 - Mar 2016

  At the Center for Research in Health and Economics (CRES-UPF), top responsibilities on research and consulting projects in health economics, policy and management, for public and private stakeholders. Also responsible for the development and management areas of the center, until 2014. At the pharmaceutical company Almirall, holding a part-time position as advisor on pharmacoeconomics on behalf of CRES-UPF, until Dec 2015. Regular teaching activities in different graduate programs in health economics, policy and management: -Co-Director of the MSc degree in Health Policy and Management MADS, at UPF. http://www.e-mads.org/ -Co-Director of the Diploma on Health Technology Assessment, at UPF. http://www.fgcasal.org/aeets/.



Almirall

• Spain
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Health economist

  • Sep 2012 - Dec 2015

  Responsible for the CRES-UPF line of support on pharmacoeconomics to Almirall's Price, Reimbursement and Market Access processes in the Spanish market. Responsible for the CRES-UPF line of support on pharmacoeconomics to Almirall's Price, Reimbursement and Market Access processes in the Spanish market.



Vall d'Hebron Institute of Oncology (VHIO)

• Spain
• Research Services
• 400 - 500 Employee

• Managing Director

  • Feb 2009 - Jul 2011

  Responsible for managing the Institute, depending on the highest governing bodies of the Foundation (Board and Executive Committee) and the Chief Scientist (Dr. Jose Baselga), in turn, Chief of Oncology at the Hospital Universitari Vall d 'Hebron. Responsible for managing the Institute, depending on the highest governing bodies of the Foundation (Board and Executive Committee) and the Chief Scientist (Dr. Jose Baselga), in turn, Chief of Oncology at the Hospital Universitari Vall d 'Hebron.



USP hospitales

• Barcelona

• Different top management positions

  • Feb 2001 - Jan 2009

  - Corporate Strategic Planning Director (January 2009-September 2007) Responsible for developing proposals and set the strategic lines of the group, designing new business lines and support the decisions of international and national expansion of the group. Coordination of the development of the business plan under way at hospitals and group. Responsible for trend analysis results in hospitals in Spain. - New Hospital Project Director and CEO Deputy, Institut Universitari Dexeus (IUD) (May 2005-August 2007). Responsible for the transition to the new hospital, including the hiring of medical team, and their relocation in the new facilities, reorganization of general services, etc.. Responsible for the moving, a process carried with "in-house" resources. Responsible for sealing and delivering the old building. - Corporate Director of New Projects (January 2004-April 2005). The same responsibilities as in the previous period and also responsible for organizational development projects in Spain ( new hospital in Madrid, New IUD, Ave Maria in Seville, partnership with GE, etc.).. Elaborating the Business Plan which led to the first MBO. - General Services Director and Deputy Corporate CEO (December 2002-December 2003). Responsible for monitoring and control national hospitals, and for developing a strategic plan that gave the first MBO, responsible for subcontracting and general support services (cleaning, catering, laboratory, call center, etc..). - Corporate Director of Strategy and Negotiations (September 2001-November 2002). Responsible for developing the strategic plan of the hospital and supervising the relationships with third parties (suppliers, outsourced services companies, works and maintenance). - General Director and CEO, Smartmission (January 2001-July 2001). Company owned by USP, which goal was to create a centralized purchasing entity for drugs and medical supplies.



Salutia.com

• Madrid

• Director of business development and connectivity

  • May 2000 - Jan 2001

  Start-up internet company for the development of software serving as support in administrative transactions in the private health care insurance sector in Spain. Start-up internet company for the development of software serving as support in administrative transactions in the private health care insurance sector in Spain.



Ministerio de Sanidad

• Spain
• Government Administration
• 700 & Above Employee

• Directora Técnica de Estudios

  • Feb 1997 - May 2000

  Adviser to the Minister and the General Secretary of the Ministry, on issues regarding spending, financing and general regulation: insurance model, design proposals and participation in the negotiation of reforms in hospital management, health financing and insurance forms for special groups, review of economic evaluation analysis of new pharmaceutical product, monitoring of key economic sector indicators, design and implementation of a national model of incentives for sick leave public coverage.